AMGN 10-K Analysis: Net Income Doubled While Cash Flow Fell 13%

Amgen, the world's largest independent biotech with $36.8 billion in FY2025 revenue, reported net income that nearly doubled to $7.7 billion — an 88.5% surge that made it the strongest earnings recovery story in large-cap pharma. But operating cash flow fell 13.3%, free cash flow collapsed 22%, and the company repurchased exactly zero shares of stock.

The headline numbers looked compelling enough. Diluted EPS jumped from $7.56 to $14.23. Management guided 2026 EPS of $21.60 to $23.00 — seemingly another year of 50%+ growth. The growth portfolio was accelerating. Repatha, EVENITY, TEZSPIRE, and TEPEZZA were all posting double-digit gains. For investors watching the quarterly cadence, Amgen appeared to be a pharma recovery story firing on all cylinders. But the apparent 57% EPS growth in 2026 guidance is an illusion: FY2025 GAAP EPS was depressed by a $1.2 billion Otezla impairment and Horizon amortization. Adjusted-to-adjusted growth is likely 5-10%, not 57%.

The annual report tells a fundamentally different story. Buried in the product revenue footnote, growth products overtook legacy at-risk drugs for the first time — a structural crossover that no analyst summary highlighted. Meanwhile, accounts receivable spiked $2.8 billion on just $3.3 billion of revenue growth, a $12.3 billion debt maturity wall looms over the next three years, and every incremental dollar of invested capital is currently destroying value. The gap between what Amgen earned and what it collected is the widest in large-cap pharma — and the four drivers behind it tell completely different stories about the company's future.

The Crossover No One's Pricing

Amgen's product revenue footnote contains a structural milestone that no earnings summary captured. Growth products — Repatha, EVENITY, TEPEZZA, TEZSPIRE, BLINCYTO, and KRYSTEXXA — generated $11.4 billion in FY2025, representing 32.4% of the $35.1 billion in total product sales. Legacy at-risk drugs — Prolia, XGEVA, ENBREL, and Otezla — generated $11.0 billion, or 31.3%. For the first time in Amgen's history, the growth portfolio exceeded the legacy portfolio.

This crossover reframes the Amgen investment thesis entirely. The prevailing narrative treats the patent cliff as an approaching threat — Prolia facing biosimilar competition, ENBREL in structural decline, Otezla impaired. But the filing data shows the inflection point has already passed. The transition isn't approaching; it's more than half over. The question has shifted from "Can Amgen survive its patent cliff?" to "How fast can the growth portfolio outrun legacy erosion?"

The complication is how Amgen achieved this crossover. Unlike AbbVie, which navigated its Humira cliff through Skyrizi and Rinvoq — two drugs that command pricing premiums — Amgen's transition is volume-driven in a deflationary environment. The filing reveals the growth model explicitly.

"Total product sales increased 10% in 2025, driven by volume growth of 13%, partially offset by declines in net selling price of 3%. U.S. volume grew 13% and ROW volume grew 14%, driven by volume growth in certain brands, including Repatha, PAVBLU, EVENITY, IMDELLTRA/IMDYLLTRA and TEZSPIRE."

The ENBREL trajectory illustrates the pricing pressure ahead. In the first nine months of 2025, ENBREL's net selling price declined 30%, driven by "increased 340B Program mix, the impact of the U.S. Medicare Part D redesign and higher commercial discounts," according to the Q3 10-Q. With CMS Medicare price setting beginning in 2026, ENBREL could fall below $2 billion in annual revenue. Otezla faces the same treatment starting 2027, compounding its $1.2 billion impairment.

Amgen does hold one unique hedge: it simultaneously sells branded Prolia ($4.4 billion) and its own biosimilar denosumab, PAVBLU, at an annualized run rate of approximately $850 million. No other large-cap pharma is both the attacker and defender on the same molecule. But this doesn't resolve the structural concern — volume-driven growth in a deflationary pricing environment generates lower incremental margins than the pricing-power transitions at peers like AbbVie, whose FCF margin runs 7 percentage points higher at 29.1%.

Amgen's growth products generated $11.4 billion in FY2025 revenue, overtaking legacy at-risk drugs ($11.0 billion) for the first time, which suggests the patent cliff transition is more than 50% complete — but the crossover was achieved through volume growth, not pricing power.

The Four-Part Cash Divorce

The headline was irresistible: Amgen's net income nearly doubled, surging 88.5% to $7.7 billion. But operating cash flow moved in the opposite direction, falling 13.3% to $10.0 billion. The gap — 102 percentage points — is the widest NI-to-OCF divergence among large-cap pharma peers. AbbVie, Merck, and Johnson & Johnson all show net income and operating cash flow moving in the same direction. Amgen is the only company where earnings doubled while cash generation declined.

The standard investor response to "net income nearly doubled" is bullish. The EPS recovery from $7.56 to $14.23 triggered a valuation re-rating. But standard earnings analysis treats the cash flow divergence as a single working capital adjustment. The 10-K reveals it's actually four distinct stories with fundamentally different time horizons — and this decomposition is the key to understanding whether the earnings recovery is real.

The first component is already exhausted. The Horizon Therapeutics acquisition ($28 billion, closed 2023) required a fair-value step-up of acquired inventory that inflated cost of goods sold in FY2024, depressing gross margin to 61.5%. In FY2025, the step-up fully absorbed — inventory declined 11% despite 10% revenue growth — and gross margin recovered 570 basis points to 67.2%. This boosted net income mechanically but generated zero incremental cash. It was a one-time accounting normalization, and the effective tax rate simultaneously climbed 460 basis points to 14.1% as more income became taxable, partially offsetting the gross margin recovery with approximately $400 million in incremental tax expense.

The second component is the most concerning because its permanence is genuinely unknown. Accounts receivable spiked $2.8 billion — from $6.8 billion to $9.6 billion — a 41% increase against just 10% revenue growth. AR as a percentage of revenue jumped from 20.3% to 26.0%, equivalent to days sales outstanding stretching from approximately 74 to 95 days. The filing's explanation is brief.

"The increase in total sales deductions balance was primarily driven by an increase in gross sales and timing of payments."

A four-times divergence between AR growth and revenue growth is a forensic accounting signal. Possible explanations include growth products sold to new channels with longer payment terms, gross-to-net rebate timing shifts, or channel inventory buildups ahead of biosimilar launches. The filing's explanation is insufficient for the magnitude of the divergence, and Q1 2026 AR trajectory becomes the single most important monitoring metric for earnings quality.

The third component — capital expenditures surging 69.5% to $1.9 billion for MariTide manufacturing and pipeline expansion — is deliberate and multi-year. The fourth — $6.0 billion in debt retired, consuming fully half of operating cash flow — is structurally mandatory for the next three to five years. Together, these four drivers collapsed the cash conversion ratio from 2.81x to 1.29x in a single year. Amgen now generates barely $1.29 in operating cash for every dollar of reported net income.

Amgen's net income nearly doubled while operating cash flow fell 13.3%, creating a 102-percentage-point divergence driven by a $2.8 billion accounts receivable spike that the company attributes to "timing of payments."

The Debt Treadmill

Amgen carries $54.6 billion in total debt — a legacy of the $28 billion Horizon Therapeutics acquisition — with interest expense of $2.76 billion consuming 30.3% of operating income and interest coverage of 3.3x, the lowest among large-cap pharma peers. AbbVie has 5.2x coverage, Merck 16.3x, Johnson & Johnson 26.4x. But the unique concern isn't the absolute debt level. It's the timing.

The 10-K debt footnote reveals $12.3 billion in maturities over the next three years, including low-rate tranches that will refinance at significantly higher costs in the current rate environment.

Against operating cash flow of $10 billion and free cash flow of $8.1 billion, these maturities create a capital allocation squeeze with no room for error. Annual committed cash uses total approximately $11 to $12 billion: dividends of $5.2 billion growing 6% per year, debt maturities of $4 to $6 billion, and capex of $1.9 billion and rising. That sum exceeds annual operating cash flow.

Management's response has been to eliminate stock buybacks entirely. Amgen repurchased zero shares in FY2025 — down from $200 million in FY2024 — despite a $6.8 billion unused buyback authorization. This is not strategic discipline. It is arithmetic. The $6.0 billion of "retired" debt in FY2025 was predominantly mandatory: approximately $4.5 billion represented maturities coming due, with only $1.5 billion of discretionary de-leveraging. The near-term maturities include 2.20% and 2.60% tranches that will refinance at 5%+, adding an estimated $50 to $80 million in incremental annual interest.

"Other operating expenses for 2025 included Otezla intangible asset impairment charges of $1.2 billion."

The constraint is compounded by deteriorating acquisition quality. Amgen acquired Otezla for $13.4 billion in 2019; the $1.2 billion write-down represents a 9% capital loss with more to come as CMS Medicare pricing begins in 2027. The debt-to-equity ratio has improved dramatically — from 10.2x to 6.3x — but this was driven by equity recovery from the net income rebound, not by transformative de-leveraging.

Meanwhile, the dividend continues to grow into compressing free cash flow. The board raised the Q1 2026 dividend 6% to $2.52 per share, pushing the annualized FCF payout ratio to 67.5% — up from approximately 47.5% a year earlier. Coverage has thinned from roughly 2.1x to 1.55x. Another 10% decline in free cash flow would push coverage below 1.3x, leaving almost nothing for debt reduction beyond mandatory maturities.

Amgen faces a $12.3 billion debt maturity wall over 2026-2028, forcing it to devote more than 50% of operating cash flow to debt service and leaving zero room for stock buybacks.

The MariTide Bet: What Negative ROIIC Actually Means

Amgen's overall ROIC of 12.1% looks healthy — above its cost of capital and competitive within pharma. But ROIIC — return on incremental invested capital — tells a starkly different story. At -8.6% quarterly and -21.5% trailing twelve months, every incremental dollar of capital that Amgen has deployed is destroying value at the margin.

This metric is unique among large-cap pharma. AbbVie, Merck, and Johnson & Johnson all show positive incremental returns on capital. Amgen is the only company where the Horizon integration, MariTide manufacturing buildout, and $7.3 billion in annual R&D spend have collectively failed to generate marginal returns — even as headline ROIC remains in double digits.

The bull case for negative ROIIC is that it's structurally backward-looking. MariTide — Amgen's obesity drug candidate in Phase 3 trials with data expected in 2027 — generates zero revenue today but targets a market projected at over $100 billion by 2030. The capex surge is partially building manufacturing capacity for a drug that hasn't launched. If Phase 3 data shows competitive efficacy with Ozempic and Zepbound, MariTide could become a $5 to $10 billion revenue product, transforming the ROIIC denominator. If it fails, billions in manufacturing capacity cannot be repurposed, and ROIIC will remain negative through the decade.

There are also hidden obligations complicating the capital picture. The filing discloses substantial commitments beyond what appears on the balance sheet.

"As of December 31, 2025, we have purchase obligations of approximately $6.9 billion primarily related to (i) R&D commitments (including those related to clinical trials) for new and existing products, (ii) capital expenditures and (iii) open purchase orders... the maximum amount that may be payable in the future for agreements we have entered into with third parties is approximately $7.2 billion."

Additionally, Amgen remains under IRS examination for 2016-2018, with unrecognized tax benefits of $4.2 billion relating to transfer pricing between U.S. and foreign jurisdictions. A resolution expected in late 2026 could require substantial payments that further compress the capital available for the growth transition.

At $326 per share and 15.6x EV/EBITDA, the market isn't pricing MariTide success — but it isn't pricing ROIIC failure either. Amgen's multiple sits between Merck's depressed 11.6x (penalized for Keytruda's 2028 cliff and Gardasil's 39% decline) and AbbVie's premium 29.0x (rewarded for its successful Skyrizi/Rinvoq transition). Whether the transition succeeds depends on whether the $100 billion question — MariTide — can overcome the $12.3 billion constraint — debt — before the $8.1 billion buffer — free cash flow — erodes further.

Amgen's return on incremental invested capital turned negative at -8.6%, making it the only large-cap pharma company where newly deployed capital is destroying value at the margin.

What to Watch

The investment case for Amgen now hinges on three measurable triggers in Q1 2026 and beyond.

Revenue trajectory ($9.0-9.5 billion in Q1). Below $9.0 billion signals that biosimilar erosion on Prolia — Amgen's largest product at $4.4 billion annually — is accelerating faster than the growth portfolio can compensate. Above $9.5 billion suggests management sandbagged its 2026 guidance of $37.0 to $38.4 billion, and the crossover thesis strengthens materially.

Accounts receivable normalization. If AR grows another $500 million sequentially to breach $10 billion while revenue remains flat, the "timing of payments" explanation becomes untenable and signals structural earnings quality deterioration. If AR declines toward $9.0 billion, the FY2025 spike was genuinely timing-related and the bear case on cash quality weakens.

Prolia quarterly trajectory. As the largest individual product, Prolia's biosimilar erosion rate sets the pace for the crossover thesis. CVS has already announced a preferred biosimilar swap. If quarterly revenue drops below $1.0 billion from its current approximately $1.1 billion run rate, the crossover cushion — currently just $407 million — could reverse.

Further out, MariTide Phase 3 data in 2027 represents a binary catalyst that either validates or condemns the negative ROIIC as forward investment versus permanent capital destruction. And the 10-year Treasury rate determines whether the $12.3 billion maturity wall is manageable or punitive — every 100 basis points above 4.5% adds roughly $120 million in annual refinancing cost.

At $326, the market implies approximately 3% annual revenue growth with stable free cash flow margins — a modest assumption that the filing simultaneously supports and complicates. The growth crossover validates the transition thesis. But 22% free cash flow compression, a 102-point earnings-to-cash divergence, and the only negative ROIIC in large-cap pharma suggest the quality of that transition matters more than its direction. Amgen is past the hardest part of its patent cliff. Whether it can fund the other side is what the next four quarters will decide.

Frequently Asked Questions

Has Amgen's patent cliff already peaked?

Partially, yes. Amgen's growth portfolio — Repatha, EVENITY, TEPEZZA, TEZSPIRE, BLINCYTO, and KRYSTEXXA — generated $11.4 billion in FY2025, overtaking the legacy at-risk portfolio (Prolia, XGEVA, ENBREL, Otezla) at $11.0 billion for the first time. This crossover suggests the revenue inflection point has passed and the transition is more than 50% complete. However, the cliff isn't over: Prolia ($4.4 billion, the largest single product) faces active biosimilar competition with CVS preferring biosimilar PAVBLU, and ENBREL's net selling price has already declined 30% in nine months. Management's 2026 guidance of $37.0 to $38.4 billion (midpoint +2.6% growth) reflects the drag from legacy erosion partially offsetting growth product gains.

Is Amgen's dividend safe?

Yes for now, but the cushion is thinning rapidly. Amgen raised its Q1 2026 dividend to $2.52 per share, a 6% increase that implies an annualized $10.08 per share. Against FY2025 free cash flow per share of $14.94, the FCF payout ratio is 67.5% — up from approximately 47.5% a year earlier. Coverage of 1.55x has shrunk 30% in one year. If free cash flow compresses another 10-15% in FY2026 from continued capex growth and working capital headwinds, coverage would approach 1.3x — still safe, but leaving almost nothing for debt reduction or opportunistic investment beyond mandatory maturities.

Why did net income nearly double while cash flow declined?

Four distinct factors explain the 102-percentage-point divergence. First, the Horizon acquisition inventory step-up that inflated COGS in FY2024 was fully absorbed, boosting gross margin 570 basis points — this lifted net income but generated no incremental cash and is now exhausted. Second, accounts receivable spiked $2.8 billion (41%) against only 10% revenue growth, draining cash from operations. Third, capital expenditures surged 69.5% for MariTide manufacturing and pipeline expansion. Fourth, $6.0 billion of debt was retired, consuming 50% of operating cash flow. The critical insight: each component has a different time horizon — exhausted, unknown, multi-year, and mandatory — making the aggregate divergence far more complex than a single working capital adjustment.

How does Amgen's debt compare to pharma peers?

Amgen's $54.6 billion in total debt and 3.3x interest coverage make it the most leveraged large-cap pharma by a significant margin. AbbVie carries $65 billion in debt but generates 5.2x interest coverage (58% better than Amgen). Merck has 16.3x coverage and Johnson & Johnson has 26.4x. What makes Amgen's debt profile uniquely concerning isn't the absolute level — it's the timing: $12.3 billion matures in 2026-2028, including low-rate tranches (2.20%, 2.60%) that will refinance at 5%+ in the current rate environment, adding tens of millions in incremental annual interest expense.

What is MariTide and why does it matter?

MariTide is Amgen's obesity drug candidate — a GLP-1 receptor agonist and GIP receptor antagonist — currently in Phase 3 trials with data expected in 2027. It generates zero revenue today but targets an obesity market projected at over $100 billion by 2030. It matters because the capex surge (up 69.5% in FY2025) partly funds MariTide manufacturing buildout, and negative ROIIC (-8.6%) partially reflects this front-loaded investment with deferred payoff. If Phase 3 data is competitive with Ozempic and Zepbound, MariTide could become a $5-10 billion revenue product. If it fails, Amgen has invested billions in manufacturing capacity it cannot repurpose.

What does negative ROIIC mean for Amgen investors?

ROIIC (Return on Incremental Invested Capital) measures whether newly invested capital is generating returns above its cost. Amgen's ROIIC of -8.6% quarterly and -21.5% trailing twelve months means every incremental dollar of capital is destroying value at the margin. This doesn't mean the entire business is failing — overall ROIC remains a healthy 12.1% — but it does mean the Horizon integration, MariTide investment, and pipeline spend are not yet producing returns. Among comparable peers, this is unique: AbbVie, Merck, and Johnson & Johnson all show positive incremental returns on capital.

How does the IRA specifically affect Amgen?

Amgen faces IRA pricing pressure through three channels. ENBREL has been selected for CMS Medicare price setting beginning 2026, and its net selling price already declined 30% in nine months from 340B program expansion and Medicare Part D redesign. Otezla has been selected for Medicare pricing beginning 2027, compounding the $1.2 billion impairment already taken. And structurally, Amgen's growth model of 13% volume growth offset by 3% price decline is fundamentally different from peers who maintain pricing power — when government-mandated price cuts layer on top of an already-discounting model, margin compression accelerates. Growth products like Repatha and EVENITY are not yet subject to IRA pricing, providing a 5-7 year runway before those drugs face similar pressure.

Should investors worry about the $2.8 billion accounts receivable spike?

This deserves close monitoring. AR grew 41% ($6.8 billion to $9.6 billion) while revenue grew only 10% — a four-times divergence. AR as a percentage of revenue increased from 20.3% to 26.0%, equivalent to days sales outstanding stretching from approximately 74 to 95 days. The filing attributes this to "increase in gross sales and timing of payments," but this explanation is insufficient for a four-times divergence. If Q1 2026 shows AR continuing to grow faster than revenue, it signals earnings quality deterioration. If AR normalizes back toward $9.0 billion, the spike was likely year-end timing and the concern diminishes significantly.

How does Amgen's growth crossover compare to AbbVie's Humira transition?

Both companies have crossed the point where growth products exceed legacy at-risk drugs. The critical difference is the growth mechanism. AbbVie's transition was pricing-power-driven — Skyrizi and Rinvoq command premium pricing in competitive but not commoditized markets — meaning margins improve through the transition. Amgen's transition is volume-driven (13% volume growth offset by 3% price decline), meaning margins face structural pressure as the mix shifts. AbbVie also carries higher interest coverage (5.2x versus 3.3x) and higher FCF margin (29.1% versus 22.0%), providing more financial flexibility through the transition period.

What would make this thesis wrong?

Three specific data points would falsify the thesis. First, AR normalization in Q1 2026 — if days sales outstanding returns toward 74 days, the cash-earnings divergence was temporary and the earnings quality concern weakens. Second, MariTide Phase 3 success in 2027 — best-in-class efficacy data would validate the negative ROIIC as forward investment, not capital destruction. Third, a 10-year Treasury below 3.5% — this would reduce refinancing costs on the $12.3 billion maturity wall and ease the capital allocation constraint. Any two of these three conditions would shift the thesis from "growth crossover complicated by cash deterioration" to "confirmed transition with temporary headwinds."

Why did Amgen stop buying back stock entirely?

It's arithmetic, not caution. Committed annual cash uses total approximately $11-12 billion: dividends ($5.2 billion, growing 6% per year), debt maturities ($4-6 billion per year through 2028), and capital expenditures ($1.9 billion and rising). Against operating cash flow of $10 billion, there is simply no room for buybacks. The company stated its priorities explicitly: "both reduce our debt and return capital to shareholders through the payment of cash dividends." The $6.8 billion buyback authorization sits unused, and repurchases will likely resume only after the 2026-2028 maturity wall clears — potentially 2029 at the earliest.

What should investors watch in Q1 2026?

Three monitoring triggers matter most. First, revenue relative to the $9.0-9.5 billion range — below $9.0 billion signals biosimilar erosion is accelerating faster than growth products can compensate; above $9.5 billion suggests management sandbagged 2026 guidance. Second, accounts receivable trajectory — another $500 million or more sequential increase to $10 billion would mean the "timing" explanation fails and earnings quality becomes a serious concern. Third, Prolia's quarterly revenue specifically — as the largest product ($4.4 billion annual), its biosimilar erosion rate sets the pace for the entire crossover thesis and determines how quickly the $407 million growth-over-legacy cushion either widens or reverses.

Methodology

Data Sources

This analysis is based on Amgen's FY2025 10-K filed February 13, 2026 (CIK: 0000318154), cross-referenced with the Q3 2025 10-Q for product-level revenue breakdowns, IRS dispute disclosure, and ENBREL pricing data. Financial metrics (revenue, income statement, balance sheet, cash flow, returns, and valuation multiples) are sourced from the MetricDuck automated pipeline, which extracts and calculates metrics from SEC XBRL filings. Peer data for AbbVie, Merck, and Johnson & Johnson uses the same MetricDuck pipeline for consistency. Product revenue categorization (growth, legacy, mature) is analyst judgment based on patent status, biosimilar competition, and growth trajectory — not filing-defined categories. The debt maturity schedule was reconstructed from 40+ individual tranches in the 10-K debt footnote, with EUR and GBP tranches converted at footnote-reported USD equivalents.

Limitations

• Single-segment reporting. Amgen reports as one segment (Human Therapeutics). Margins cannot be decomposed by therapeutic area. The growth-legacy crossover uses product revenue, not segment profitability.
• AR explanation gap. The filing's "timing of payments" explanation for the $2.8 billion AR increase cannot be independently verified without quarterly product-level AR breakdowns, which Amgen does not disclose.
• ROIIC is backward-looking. ROIIC structurally penalizes companies making large upfront investments (MariTide manufacturing) with deferred payoffs. The negative reading may be mechanically temporary rather than indicative of capital misallocation.
• 2026 guidance GAAP vs. non-GAAP. EPS guidance of $21.60-$23.00 is non-GAAP. The apparent 57% growth from GAAP $14.23 is misleading. We estimate adjusted growth of 5-10%, but cannot independently calculate Amgen's non-GAAP adjustments from 10-K data alone.
• No forward consensus data. Analysis is based solely on company filings and pipeline data. No sell-side estimates, price targets, or analyst models are incorporated.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in AMGN, ABBV, MRK, or JNJ. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and the MetricDuck automated extraction pipeline, and may contain errors or omissions from the automated extraction process. Investors should conduct their own due diligence before making investment decisions.